Long-term effectiveness of izokibep in adults with active PsA

Izokibep is a unique interleukin-17A  inhibitor with a molecular size of about one-tenth that of a monoclonal antibody. Hence, it has a high inhibitory potency and the potential for significant tissue penetration. According to a press statement from its manufacturer, ACELYRIN, patients with psoriatic arthritis (PsA) have shown favorable safety and efficacy results after 46 weeks of treatment with the izokibep. 

The late-stage clinical biopharma company dedicated to accelerating the discovery and delivery of transformational immunology therapies has released the long-term 46-week data from a worldwide phase 2 study of izokibep in PsA. Positive week 16 results for the medication were previously published at the American College of Rheumatology (ACR) Convergence 2022, with patients using izokibep 80 mg displaying “significant and clinically relevant” benefits. Last year’s European Alliance of Associations for Rheumatology and ACR data were presented for izokibep during the 46-week period. Philip J, Director of Rheumatology Research at the Swedish Medical Center, Mease, who is a Clinical Professor at the University of Washington School of Medicine and an investigator in the izokibep PsA study, noted that the study showed continued and marked improvements in key aspects of psoriatic arthritis, including joint pain, skin psoriasis, and enthesitis.

In this randomized, double-blind, placebo-controlled Phase 2 trial, 135 patients with active PsA from 28 sites were randomly administered izokibep 40 mg, 80 mg, or placebo. According to the announcement, at 46 weeks, 79% of patients who received izokibep 80 mg reached ACR50, 50% achieved ACR70, and 71% achieved Psoriasis Area and Severity Index (PASI) score 100. Furthermore, 89% of patients in this cohort had their enthesitis resolved. In the 40 mg cohort, about 50% of patients attained ACR50, 33% attained ACR70, and 50% attained PASI50. About 83% of these individuals had their enthesitis resolved. Finally, among the patients who received placebo before switching to izokibep at week 16, 73% reached ACR50, 64% achieved ACR70, and 67% achieved PASI100, while 80% had enthesitis remission.

The long-term data from the worldwide phase 2 study of izokibep in PsA is promising, with patients showing favorable safety and efficacy results after 46 weeks of treatment. The high percentage of patients who achieved significant improvements in joint pain, skin psoriasis, and enthesitis, along with the medication’s generally well-tolerated profile, highlights the potential for izokibep to be a transformative immunology therapy for psoriatic arthritis.

Reference

  1. Acelyrin, Inc. INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy. https://acelyrin.com/press/acelyrin-announces-magnitude-of-clinical-responses-with-izokibep-in-psoriatic-arthritis-continues-to-improve-with-longer-duration-of-therapy
error: Content is protected !!